Skip to main content

BRIEF RESEARCH REPORT article

Front. Pharmacol.
Sec. Translational Pharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1505022
This article is part of the Research Topic Emerging Horizons of Metformin: Exploring Recent Advances and Addressing Challenges in Research and Clinical Utilization View all articles

Metformin Dosage and Galectin-3 Levels: Insights from PCOS Patients Preparing for IVF

Provisionally accepted
Valentina N Nikolic Valentina N Nikolic *Milan Stefanović Milan Stefanović Dejan Mitić Dejan Mitić Slavica Sunarić Slavica Sunarić Vladana Stojiljković Vladana Stojiljković Hristina TRajković Hristina TRajković Aleksandra Ignjatovic Aleksandra Ignjatovic Dragana Stokanovic Dragana Stokanovic
  • University of Niš, Niš, Serbia

The final, formatted version of the article will be published soon.

    This study explores the impact of metformin dosage and hyperprolactinemia on galectin-3 levels in women with Polycystic Ovary Syndrome (PCOS), providing novel insights into their roles in the metabolic and hormonal management of the condition. A cohort of 53 women, diagnosed using the Rotterdam criteria and undergoing in vitro fertilization (IVF) preparation, was analyzed to determine how these factors influence galectin-3, a biomarker in PCOS. Using high-performance liquid chromatography to measure metformin concentrations and ELISA for galectin-3, our results revealed that both metformin dosage and hyperprolactinemia significantly statistically associated withpredict galectin-3 levels, while body mass index (BMI) showed no significant association. These findings challenge prior assumptions and suggest that galectin-3 may be regulated via pathways independent of metformin pharmacokinetics. Notably, the correlation between galectin-3 levels and metformin concentration was either absent or weak after adjusting for the daily dose, indicating that treatment duration and dosage, rather than absolute drug levels, may more critically influence galectin-3. This study offers deeper insights into the role of personalized metformin dosing in managing PCOS, enhancing the understanding of metabolic and hormonal regulation in this condition, and laying the groundwork for future targeted therapies.

    Keywords: Polycystic ovary syndrome (PCOS), galectin-3, Metformin, Hyperprolactinemia, Body Mass Index, Metabolic pathways, Insulin Resistance

    Received: 01 Oct 2024; Accepted: 20 Dec 2024.

    Copyright: © 2024 Nikolic, Stefanović, Mitić, Sunarić, Stojiljković, TRajković, Ignjatovic and Stokanovic. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Valentina N Nikolic, University of Niš, Niš, Serbia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.